Advanced

Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.

Ansari, Daniel LU ; Rosendahl, Ann LU ; Elebro, J and Andersson, Roland LU (2011) In British Journal of Surgery 98. p.1041-1055
Abstract
BACKGROUND:



Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis. There is a need to identify prognostic subtypes of PDAC to predict clinical and therapeutic outcomes accurately, and define novel therapeutic targets. The purpose of this review was to provide a systematic summary and review of available data on immunohistochemical (IHC) prognostic and predictive markers in patients with PDAC.

METHODS:



Relevant articles in English published between January 1990 and June 2010 were obtained from PubMed searches. Other articles identified from cross-checking references and additional sources were reviewed. The inclusion was limited to studies evaluating IHC markers in a multivariable... (More)
BACKGROUND:



Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis. There is a need to identify prognostic subtypes of PDAC to predict clinical and therapeutic outcomes accurately, and define novel therapeutic targets. The purpose of this review was to provide a systematic summary and review of available data on immunohistochemical (IHC) prognostic and predictive markers in patients with PDAC.

METHODS:



Relevant articles in English published between January 1990 and June 2010 were obtained from PubMed searches. Other articles identified from cross-checking references and additional sources were reviewed. The inclusion was limited to studies evaluating IHC markers in a multivariable setting.

RESULTS:



Database searches identified 76 independent prognostic and predictive molecular markers implicated in pancreatic tumour growth, apoptosis, angiogenesis, invasion and resistance to chemotherapy. Of these, 11 markers (Ki-67, p27, p53, transforming growth factor β1, Bcl-2, survivin, vascular endothelial growth factor, cyclo-oxygenase 2, CD34, S100A4 and human equilibrative nucleoside transporter 1) provided independent prognostic or predictive information in two or more separate studies.

CONCLUSION:



None of the molecular markers described can be recommended for routine clinical use as they were identified in small cohorts and there were inconsistencies between studies. Their prognostic and predictive values need to be validated further in prospective multicentre studies in larger patient populations. A panel of molecular markers may become useful in predicting individual patient outcome and directing novel types of intervention. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Surgery
volume
98
pages
1041 - 1055
publisher
John Wiley & Sons
external identifiers
  • wos:000292739400003
  • pmid:21644238
  • scopus:79960006148
ISSN
1365-2168
DOI
10.1002/bjs.7574
language
English
LU publication?
yes
id
772020b5-4a9e-4ea3-8e81-88a63358a501 (old id 2008467)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21644238?dopt=Abstract
date added to LUP
2011-07-04 11:28:46
date last changed
2017-10-01 04:59:16
@article{772020b5-4a9e-4ea3-8e81-88a63358a501,
  abstract     = {BACKGROUND:<br/><br>
<br/><br>
Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis. There is a need to identify prognostic subtypes of PDAC to predict clinical and therapeutic outcomes accurately, and define novel therapeutic targets. The purpose of this review was to provide a systematic summary and review of available data on immunohistochemical (IHC) prognostic and predictive markers in patients with PDAC.<br/><br>
METHODS:<br/><br>
<br/><br>
Relevant articles in English published between January 1990 and June 2010 were obtained from PubMed searches. Other articles identified from cross-checking references and additional sources were reviewed. The inclusion was limited to studies evaluating IHC markers in a multivariable setting.<br/><br>
RESULTS:<br/><br>
<br/><br>
Database searches identified 76 independent prognostic and predictive molecular markers implicated in pancreatic tumour growth, apoptosis, angiogenesis, invasion and resistance to chemotherapy. Of these, 11 markers (Ki-67, p27, p53, transforming growth factor β1, Bcl-2, survivin, vascular endothelial growth factor, cyclo-oxygenase 2, CD34, S100A4 and human equilibrative nucleoside transporter 1) provided independent prognostic or predictive information in two or more separate studies.<br/><br>
CONCLUSION:<br/><br>
<br/><br>
None of the molecular markers described can be recommended for routine clinical use as they were identified in small cohorts and there were inconsistencies between studies. Their prognostic and predictive values need to be validated further in prospective multicentre studies in larger patient populations. A panel of molecular markers may become useful in predicting individual patient outcome and directing novel types of intervention.},
  author       = {Ansari, Daniel and Rosendahl, Ann and Elebro, J and Andersson, Roland},
  issn         = {1365-2168},
  language     = {eng},
  pages        = {1041--1055},
  publisher    = {John Wiley & Sons},
  series       = {British Journal of Surgery},
  title        = {Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.},
  url          = {http://dx.doi.org/10.1002/bjs.7574},
  volume       = {98},
  year         = {2011},
}